Close Menu

NEW YORK- A consortium led by Vancouver, Canada-based Canexia Health (formerly Contextual Genomics) has launched a C$2,590,500 (US$1.9 million) initiative that aims to improve access to testing and treatment options for Canadian cancer patients during the coronavirus pandemic.

The initiative, named Project ACTT (Access to Cancer Testing and Treatment), will deploy a liquid biopsy test that only requires a blood draw for cancer treatment selection, eliminating the need for most patients to travel to a hospital for biopsies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.